Evidence map›Paper›PMID 41180305›Full record

ArticlePPAR research2025

Single-Nuclei RNA Sequencing Shows the Engagement of PPAR-Delta Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR-Delta Agonist Seladelpar.

Tomoo Yamazaki, Yongqiang Yang, David Schöler, Yoshimi Yukawa-Muto, Tetsuya Kouno, Aenne Harberts, Sadatsugu Sakane, Linton Freund, Cynthia L Hsu, Thomas C Whisenant and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PPAR research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tomoo YamazakiDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-6958-1366
Yongqiang YangDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
David SchölerDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-2736-9778
Yoshimi Yukawa-MutoDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Tetsuya KounoDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Aenne HarbertsDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-0143-8106
Sadatsugu SakaneDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-6306-4621
Linton FreundDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Cynthia L HsuDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-2604-1340
Thomas C WhisenantDepartment of Surgery, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-2838-1605
Sara Brin RosenthalDepartment of Surgery, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-6548-9658
Tatiana KisselevaDepartment of Surgery, University of California San Diego, San Diego, California, USA.
Edward E CableCymaBay Therapeutics, Fremont, California, USA.ORCID https://orcid.org/0000-0002-9268-968X
Bernd SchnablDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-6281-825X

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tatiana Kisseleva · 2019 to 2026
$10.8M
Microbiome and Intestinal Innate Immune Response in Alcoholic Liver DiseaseR37AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2021 to 2026
$2.5M
Multidisciplinary Research Training in Digestive Physiology and DiseasesT32DK142622 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, ROHIT LOOMBA · 2025 to 2026
$738k
Role of gut microbial ethanol production in alcohol use disorder and alcohol-associated liver diseaseR00AA031328 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Cynthia Li-Shin Hsu · 2025 to 2026
$497k
Role of gut microbial ethanol production in alcohol use disorder and alcohol-associated liver diseaseK99AA031328 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HSU, CYNTHIA LI-SHIN · 2023 to 2024
$351k
BLRD VA I01 BX004594NIAAA NIH HHS K99 AA031328NIAAA NIH HHS R00 AA031328NIAAA NIH HHS R37 AA020703NIDDK NIH HHS P30 DK120515NIDDK NIH HHS T32 DK142622
6 · The paper itself

Abstract

Background and Aims: The selective peroxisome proliferator-activated receptor delta (PPARD) agonist seladelpar reduces liver injury and modulates bile acid metabolism in preclinical models. Seladelpar was recently approved for the secondary treatment of primary biliary cholangitis (PBC). Despite its beneficial effects for liver diseases, the target cells of seladelpar on a single-cell level remain unknown. This study is aimed at investigating the effect of seladelpar on single liver cells. Methods and Results: CD-1 mice were gavaged with vehicle or seladelpar (10 mg/kg body weight), and the liver was harvested 6 h later. Single-nuclei RNA sequencing (snRNA-seq) analysis showed the engagement of PPARD target genes primarily in hepatocytes and cholangiocytes by seladelpar. The top two upregulated genes, Conclusion: The selective PPARD agonist seladelpar induced PPARD-responsive genes primarily in hepatocytes and cholangiocytes. Seladelpar upregulated

Indexed as

liver nonparenchymal cellsmetabolic dysfunction–associated steatohepatitisperoxisome proliferator–activated receptorsprimary biliary cholangitisRNA sequencing

Identifiers

PMID41180305
PMCPMC12575037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.